FDA warned Orphic Nutrition that its supplement capsules and gummies are unapproved new drugs because website claims say they treat diseases.
What happened
FDA reviewed Orphic Nutrition's website and Amazon storefront in March 2021 and found it took orders for seven supplement products. FDA cited many product claims that the supplements treat or prevent diseases, including diabetes, high blood pressure, cancer, colds/flu, and joint disease. FDA therefore calls the products drugs, unapproved new drugs, and—for six products—misbranded for lacking adequate directions for use.
What FDA found
The website and Amazon listings claim the supplements cure, mitigate, treat, or prevent diseases such as diabetes, high blood pressure, cancer, colds, flu, and arthritis, which makes them drugs under the law.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]The products are 'new drugs'—products that need FDA approval before sale—because they are not generally recognized as safe and effective for those uses and FDA has not approved them.
FD&C Act sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]Six products are misbranded—improperly labeled—because they lack adequate directions for a layperson to use them safely for the diseases they claim to treat.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Shipping or selling these misbranded drugs in interstate commerce violates the Act.
FD&C Act section 301(a) [21 U.S.C. 331(a)]
What FDA wants
FDA asks Orphic Nutrition to notify it in writing within 15 working days of receipt of the letter about specific steps taken to correct the violations, how recurrence will be prevented, and to include supporting documents; if it cannot finish, it must explain why and give a completion date.
Who should pay attention
- supplement brands selling online or on Amazon
- companies making disease-treatment claims for dietary supplements
- quality and regulatory teams reviewing website and marketplace claims
This is a summary. Read the original letter on fda.gov.